Marseille founders have access to early venture, angel networks, industrial innovation and regional development capital. Those are different funding lanes. A prototype, a first customer and an established growing company should not start with the same investor queue.
Compare 15 provider families, including 5 documented local or regional routes. Start with the decision framework, use the comparison to screen candidates and save the evidence in the worksheet before you approach anyone.
Match your Marseille business to the right funding lane
| Your situation | Research first | Prepare or clarify |
|---|---|---|
| Pre-seed or seed product development | Compare Obratori, Provence Angels and relevant national early-stage investors. | Prepare the product, evidence and next validation milestone. |
| A regional company after proof of concept and a first customer | Research the relevant Région Sud Investissement route. | Map private co-investment and regional activity requirements. |
| Logistics, transport or strategically relevant industry technology | Investigate the CMA CGM venture route and ZEBOX separately. | Explain operating relevance, keeping commercial pilots distinct from equity. |
| Established company growth or transition | Compare the appropriate Smalt or Tertium strategy. | Bring commercial history and a clear ownership/financing objective. |
Choose a small first wave you can research properly. Record one reason for fit, one relevant proof point and the next unanswered question for each investor. Move a name out of the active queue when the stage, sector or geographic conditions do not fit.
Compare 15 local and wider investor routes
The connection column distinguishes a documented city or regional route from a wider mandate. It does not imply that every provider has an office here. Initial investment stages and follow-on support are different. This selective list is unranked; each provider family counts once.
| Investor or network | Connection | Entry-stage distinction | Company focus |
|---|---|---|---|
| Provence Angels | Local / regional: Marseille and PACA; national company coverage | Early company and growth cases; member-specific | Innovative scalable businesses |
| Obratori | Local / regional: Marseille office; wider company remit | Pre-seed and seed | Consumer, B2B software, health, deep tech and green technology |
| Smalt Capital / Région Sud Investissement | Local / regional: Marseille and Région Sud; regional company activity | Post-proof-of-concept through development; vehicle-specific | Innovation, industrialization and environmental transition |
| CMA CGM Ventures / ZEBOX ecosystem | Local / regional: Marseille-rooted group; international innovation | Company-specific; incubation and investment are separate | Logistics, transport and strategically relevant technology |
| Tertium | Local / regional: Marseille; greater southeast France | Development and business transition; not idea-stage seed | Established industrial, service and technology businesses |
| Partech | Wider route: Paris office; fund-specific European and international mandates | Seed, venture and growth; separate teams | Broad seed remit; B2B software at venture stage; other specialist funds |
| Elaia | Wider route: Paris-registered manager; confirm the relevant fund's geography | Pre-seed through pre-IPO; strategy-specific | Scientific and technological innovation |
| Alven | Wider route: French-origin manager backing founders across Europe | Early-stage; confirm the current fund's entry point | Technology companies; founder and company fit |
| Serena | Wider route: Paris office; Europe and US companies in its stated scope | Pre-seed through Series A; vehicle-specific | Applied AI; energy transition; data infrastructure; impact; consumer innovation |
| Breega | Wider route: Paris and London offices; Europe and Africa activity | Pre-seed through Series A+ | Digital; climate; deep technology |
| ISAI | Wider route: Paris team; separate support for French founders established in the US | Pre-seed and first institutional rounds; separate later strategies | Technology-enabled companies |
| XAnge | Wider route: Paris, Berlin and Brussels offices; European technology focus | Seed through Series B; vehicle-specific | AI productivity; frontier technology; sustainable future |
| Sofinnova Partners | Wider route: Paris, Milan and London offices; specialist international strategies | Company creation through later development; strategy-specific | Healthcare; therapeutics; industrial biotechnology |
| 360 Capital | Wider route: Paris and Milan investment teams; European focus | Pre-seed through Series B | Deep tech; climate tech; digital-first solutions |
| Paris Business Angels | Wider route: Companies across France | Pre-seed through Series A; seed emphasis | Technology, deep tech, AI and B2B |
A first customer changes the regional-capital conversation
Région Sud Investissement’s current strategy describes early investment after proof of concept and a first client, venture investment as the business model begins to validate, and development capital as profitability emerges. Private co-investment is an important part of its model.
Write the actual evidence beside the stage label. A friendly conversation, an unpaid test and a paying client are different facts. Identify the relevant vehicle within the regional manager relationship rather than adding every product as an unrelated investor.
The Marseille logistics ecosystem offers more than one relationship
CMA CGM’s corporate venture activity and ZEBOX support different aspects of innovation. A company might seek a financing conversation, a commercial pilot or an acceleration programme. State which relationship is needed and what the product can demonstrate.
Do not promise that programme participation leads to investment or a commercial contract. A clear operating use case and evidence from authorized tests make a better approach than a general claim to be transforming logistics.
Keep growth investors out of an idea-stage first wave
Tertium’s current strategy is development and transition capital for medium-sized companies in the greater southeast. Some Smalt strategies also have later-company commercial screens. They can be useful for a growing technology business, but they are not substitutes for first validating a product.
Use national specialists where the scientific or software thesis is more relevant. The France guide remains the national owner; this page adds Marseille’s local decision framework and approach routes.
15 investors and networks to research
1. Provence Angels
Angel-investor network. Provence Angels provides an actual angel-investment network rooted in Marseille and PACA, with national coverage. Members contribute capital and operating experience. Explain the company’s evidence and the relevant expertise, then use the founder fundraising route rather than applying to become an investor.
Approach: Use Postuler et lever des fonds. Official Provence Angels information.
2. Obratori
Corporate venture investor. Obratori’s current site explicitly identifies pre-seed and seed investing and several domains beyond consumer products, including B2B SaaS, health and industrial decarbonization. Choose a real thematic connection and show the next product or market milestone. Coworking is separate from the investment decision.
Approach: Use the company investment/contact information. Official Obratori information.
3. Smalt Capital / Région Sud Investissement
Regional investment and co-investment routes. Keep Smalt’s investment products and the regional RSI mandate in one manager-level research relationship here. RSI publishes a first-client and proof-of-concept boundary for early investment and requires private co-investment. Other Smalt SME strategies have later commercial screens. Select the vehicle before approaching.
Approach: Use the appropriate founder/project route and establish private co-investment. Official Smalt Capital / Région Sud Investissement information. Additional criteria or geographic context.
4. CMA CGM Ventures / ZEBOX ecosystem
Corporate investment route. CMA CGM’s official innovation materials distinguish corporate venture investment from ZEBOX incubation and acceleration. A Marseille founder should explain the operating problem, strategic relevance and product evidence. Programme participation, a pilot and direct equity are different outcomes; the ecosystem is not counted twice.
Approach: Use the group innovation/venture contact; check ZEBOX programme terms separately. Official CMA CGM Ventures / ZEBOX ecosystem information. Additional criteria or geographic context.
5. Tertium
Regional development-capital manager. Tertium is a regional development and transition investor for medium-sized companies. It belongs in a later-company comparison, not a pre-revenue startup’s first pitch wave. Explain the growth plan, operating history and ownership objective, and keep new company capital distinct from shareholder liquidity.
Approach: Use the published company enquiry. Official Tertium information.
6. Partech
Multi-strategy venture platform. Partech has separate seed, venture and growth teams. Its seed strategy can begin very early, while the later B2B-software strategy asks a different commercial question. Identify the team and connect the company’s current evidence with the milestone the round should finance.
Approach: Use the published founder/contact information. Official Partech information.
7. Elaia
Scientific and technology investment platform. Elaia connects scientific and technological expertise with funds spanning pre-seed through pre-IPO. For a research-led company, choose the relevant strategy and show the commercialization problem. The platform’s full stage range should not be read as one unrestricted intake route.
Approach: Use the published founder/contact information. Official Elaia information.
8. Alven
Independent early-stage venture firm. Alven backs early-stage founders across Europe. A Lille company should explain its product advantage and the most convincing evidence of demand, then establish the current fund’s entry expectations with the team. It is a wider venture option, not another Lille office.
Approach: Use the published founder/contact information. Official Alven information.
9. Serena
Early-stage venture platform. Serena’s current site describes Europe-based entrepreneurs, pre-seed to Series A and a preference for leading or co-leading rounds. Explain the relevant technology and operating milestone. Lead preference is not a commitment to lead your proposed round or remove the need for other investors.
Approach: Use the published founder/contact information. Official Serena information.
10. Breega
Operator-led venture firm. Breega publishes pre-seed to Series A+ investing across digital, climate and deep technology in Europe and Africa. Pick the matching strategy and make the business problem specific. A Lille software startup and a scientific industrial venture need different evidence even within this platform.
Approach: Use the published founder/contact information. Official Breega information.
11. ISAI
Entrepreneur-backed investment platform. ISAI distinguishes French early-stage investing from a separate route for French founders already established in the US. The US strategy is not simply for any company hoping to expand there. State the current operating facts and choose the appropriate founder-facing team.
Approach: Use the published founder/contact information. Official ISAI information.
12. XAnge
European venture manager. XAnge’s current funds span seed through Series B across AI, deep tech, climate, health and vertical software. Explain which thesis fits and what the company has proved. Use Send your pitch, not the portal reserved for existing portfolio founders.
Approach: Use the published founder/contact information. Official XAnge information.
13. Sofinnova Partners
Life-sciences investment platform. Sofinnova is a wider scientific investment route with distinct strategies from company creation to later development. Establish whether the opportunity is therapeutics, medtech, digital medicine or industrial biotechnology. Prepare the underlying evidence and the development milestone rather than a generic health-sector pitch.
Approach: Use the published founder/contact information. Official Sofinnova Partners information.
14. 360 Capital
European technology venture firm. 360 Capital’s current European remit spans pre-seed to Series B across deep tech, climate and digital-first solutions. A Lille team should connect its technical advantage with a commercial use case and use the dedicated Pitch now route. Paris and Milan teams are not Lille offices.
Approach: Use the published founder/contact information. Official 360 Capital information.
15. Paris Business Angels
Angel-investor network. Despite its name, Paris Business Angels explicitly describes national coverage. That makes it a wider route for a Lille startup, not another local office. Members assess innovative companies and make their own investment decisions. Use the founder project route and show the evidence appropriate to the actual stage.
Approach: Use Déposer mon projet. Official Paris Business Angels information.
A Marseille logistics team separates three possible asks
Fictional worked example. A Marseille company has a working logistics tool and one paying pilot. It wants to validate recurring use and customer economics before scaling sales. No investor or corporate partnership is committed.
| Candidate | Next action | Why it changes the decision |
|---|---|---|
| Obratori / Provence Angels | Prepare the early product and buyer evidence. | The company needs first-commercial validation rather than mature growth capital. |
| RSI within the regional relationship | Check the first-client and co-investment conditions. | A paid pilot is relevant evidence but not a complete eligibility decision. |
| CMA CGM venture / ZEBOX | Choose investment, pilot or programme as the initial ask. | Each route makes a different decision. |
| Tertium | Track as a later development possibility. | An early pilot does not establish a medium-sized growth company. |
The aim is a more coherent queue, not the largest possible one. Connect the proposed round with an achievable milestone using the round-size planning worksheet.
Build your Marseille investor-fit worksheet
Use one card for each provider and strategy. It works in a document, spreadsheet or your Finta research notes. Keep facts, expectations and questions in separate fields.
INVESTOR FIT CARD: MARSEILLE
Company, current evidence and next funding milestone: [authorised facts]
Connection: Marseille office / Région Sud activity / wider mandate
Evidence: proof of concept / first client / repeatable sales / profitability
Ask: equity / co-investment / pilot / programme / growth capital
Private co-investor: confirmed / conditional / unidentified
Investor and specific vehicle: [current name; avoid rebrand duplicates]
Official stage, sector and geographic criteria: [URL; date]
Fit evidence: [what matches; not just a portfolio resemblance]
Mismatch or open question: [the unresolved issue]
Approach route: [founder form / network selection / general enquiry]
Relationship context: [known person; permission to ask; or public route]
Lead/co-investment status: [unknown / conditional / confirmed]
Owner, next action and follow-up date: [person; action; date]Bring the shortlist into Finta to keep investor research, relationship context and follow-up connected. Aurora can help organise the context and prepare a next move for your review. You stay in control of the approach and information shared.
Review your shortlist with Aurora, Claude or Codex
Paste the prompt with the public sources and company information you are authorised to use. Check its output against the sources before acting.
Help me research investor fit for a Marseille startup.
Company, location, current evidence and funding milestone: [authorised facts]
Candidates and official sources: [names, URLs and research dates]
Separate local offices, regional operating requirements and wider investment eligibility.
Check the specific vehicle, initial stage, sector, company conditions and public approach route.
Keep university programmes, angel networks, direct equity, grants and commercial partnerships distinct.
Count each manager or rebrand once. Do not assume a portfolio investment proves current eligibility.
Return a table: source, fit evidence, mismatch, unknown, next question and owner.
Flag missing or contradictory evidence instead of filling gaps.
Suggest a short first research wave and explain exclusions.
Do not contact anyone, submit forms or share confidential information.Keep the wider fundraising process connected with the pre-seed guide, Seed Fundraising Comprehensive Guide and investor-prospecting workflow. For national coverage, see the France investor guide.
Methodology and research date
By Finta Editorial Team. Official investor, public-institution and company materials reviewed November 13, 2026, with source-dated prior research used for discovery. 15 provider families are included: 5 documented local or regional routes and 10 wider mandates. Angel networks are identified as networks, not pooled funds. Company-building and strategic investment routes are labelled separately.
Startup Genome’s 2026 Emerging Ecosystems ranking informed city selection; it is not an investor ranking or endorsement. Current official materials support the profiles. A published thesis is not a promise of available capital, current intake or an investment outcome. Confirm open questions directly.
Not counted or kept separate:
- Smalt and RSI are grouped at manager level rather than counted as unrelated relationships.
- CMA CGM Ventures and its ZEBOX ecosystem are not double-counted; incubation is not itself a direct equity commitment.
General information, not personalised financial, legal or tax advice. Programme and company criteria are research filters, not an eligibility ruling. The cover is an editorial ecosystem illustration, not a map of investor offices or actual financing flows.